XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.3
License, Collaboration and Service Agreements - Additional Information (Detail)
$ / shares in Units, £ in Millions
 1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Jan. 15, 2021
USD ($)
Jun. 30, 2017
USD ($)
Jun. 30, 2016
USD ($)
Jun. 30, 2016
GBP (£)
May 31, 2016
USD ($)
Sep. 30, 2024
USD ($)
$ / shares
Mar. 31, 2024
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2020
USD ($)
Mar. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Jun. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
$ / shares
shares
Sep. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
$ / shares
Dec. 31, 2022
USD ($)
Sep. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Oct. 31, 2024
USD ($)
Aug. 31, 2024
USD ($)
Jun. 30, 2024
USD ($)
Jul. 31, 2023
USD ($)
Nov. 07, 2022
USD ($)
Oct. 31, 2017
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                                  
Issuance of stock, value               $ 220,000             $ 220,000                    
Common stock, par value | $ / shares           $ 0.001               $ 0.001   $ 0.001                  
Proceeds from sale of common stock to related party                           $ 0 220,000                    
Revenue recognized           $ 65,000   218,000           319,000 710,000                    
Milestone payment           225,000,000               225,000,000                      
Total Milestone                               $ 95,000,000                  
Deferred revenue, current           788,000               788,000   2,132,000                  
GSK SPA [Member]                                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                                  
Remaining transaction price allocated to the performance obligations           64,700,000               64,700,000                      
Milestone payment           21,200,000               21,200,000                      
Total Milestone           30,000,000               30,000,000                      
Initial Payments to Perform the Obligations                                 $ 66,000,000                
Discount on Obligations                                 1,300,000                
GSK SPA [Member] | Research And Development Services Related To Upcoming Milestones [Member]                                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                                  
Revenue recognized                                 19,000,000                
GSK SPA [Member] | License and Know-How Transfer [Member]                                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                                  
Remaining transaction price allocated to the performance obligations                                 64,700,000                
Performance Obligation Allocated Transaction Price                                 45,700,000                
Vertex License Agreement [Member]                                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                                  
License agreement research and development expense related to achievement of regulatory milestones           0   0           $ 0 0                    
Contract termination period                           10 years                      
Nonrefundable upfront payments         $ 500,000                                        
Potential milestone payment upon achievement of specified clinical, regulatory and commercial milestones         $ 80,200,000                                        
Contract termination period if no material development or commercialization occurs                           1 year                      
GSK License Agreement [Member]                                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                                  
Performance Obligation Allocated Transaction Price           7,800,000   23,200,000           $ 17,700,000 24,200,000                    
Deferred revenue, current           30,900,000               30,900,000                      
GSK License Agreement [Member] | Research And Development Services Related To Upcoming Milestones [Member]                                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                                  
Total potential additional milestones                               3,200,000                  
GSK License Agreement [Member] | Amendment 2 [Member] | First Milestone [Member]                                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                                  
Milestone payment                                         $ 1,200,000        
GSK License Agreement [Member] | Glaxo Smith Kline [Member]                                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                                  
Milestone payment                               23,800,000   $ 23,800,000 $ 23,800,000     $ 23,800,000   $ 66,000,000  
Reduction In Subsequent Payments by GSK to the Company                                               50.00%  
GSK License Agreement [Member] | Glaxo Smith Kline [Member] | Amendment 2 [Member]                                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                                  
Milestone payment                                             $ 4,300,000    
GSK License Agreement [Member] | Glaxo Smith Kline [Member] | Amendment 2 [Member] | Second Milestone [Member]                                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                                  
Milestone payment                                       $ 1,300,000          
GSK License Agreement [Member] | Glaxo Smith Kline [Member] | Amendment 4 [Member]                                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                                  
Milestone payment                                       $ 800,000          
GSK License Agreement [Member] | GSK SPA [Member]                                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                                  
Milestone payment           23,800,000 $ 23,800,000             23,800,000   64,700,000   $ 23,800,000 $ 23,800,000       $ 30,000,000    
Total Received Milestone               30,000,000             30,000,000 95,000,000                  
Significant financing component                               2,500,000                  
Total Milestone                               95,000,000                  
Research and development services performance obligation           8,800,000               8,800,000   2,500,000                  
Meiji License Agreement [Member]                                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                                  
Nonrefundable upfront payments   $ 600,000                                              
Sublicense fee payable to counter party                                 7,500,000                
Potential milestone payments upon achievement of specified condition                                                 $ 1,000,000
License agreement fixed assets related payments                       $ 1,600,000                          
Potential milestone payments upon completion and delivery of results of a clinical study             $ 1,000,000                                    
Future milestone payments                           1,000,000                      
Sublicence Fee Paid to Counter Party                                 $ 6,600,000                
Remaining Sublicence Fee Paid to Counter Party                               $ 900,000                  
Cantab Related Agreements [Member]                                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                                  
Potential milestone payment upon achievement of specified commercial milestone       £ 5.0                   6,700,000                      
License agreement research and development expense related to achievement of regulatory milestones                         $ 0 $ 0                      
Potential milestone payment upon achievement of specified clinical, regulatory and commercial milestones     $ 5,800,000                                            
Everest License Agreement [Member]                                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                                  
Period of option granted on an agreement                           12 months                      
Upfront payment received                     $ 3,000,000                            
Potential milestone payments upon completion and delivery of results of a clinical study                   $ 2,000,000                              
Revenue recognized           0   0           $ 0 0                    
Milestone payment           34,000,000               34,000,000                      
Everest License Agreement [Member] | SPR 206 [Member]                                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                                  
Upfront payment received                     2,000,000                            
Milestones payment received $ 2,000,000                                                
Everest License Agreement [Member] | SPR 741 [Member]                                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                                  
Upfront payment received                     $ 1,000,000                            
Everest License Agreement [Member] | Maximum [Member]                                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                                  
Agreement termination period upon written notice 180 days                                                
Everest License Agreement [Member] | Maximum [Member] | SPR 206 [Member]                                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                                  
Receivable amount upon achievement of certain milestone $ 38,000,000         59,500,000               $ 59,500,000                      
Everest License Agreement [Member] | Minimum [Member]                                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                                  
Agreement termination period upon written notice 90 days                                                
Pfizer License and Share Purchase Agreements [Member]                                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                                  
Receivable amount upon achievement of certain milestone                 $ 900,000                                
Milestones payment received                 5,000,000                                
Issuance of stock, shares | shares                           2,362,348                      
Issuance of stock, value                           $ 27,500,000                      
Remaining transaction price allocated to the performance obligations           12,500,000               12,500,000                      
Revenue recognized           100,000   $ 200,000           300,000 $ 700,000                    
Premium associated freestanding equity                           12,500,000                      
Performance Obligation Allocated Transaction Price                 5,000,000                                
Deferred revenue, current           $ 12,600,000               12,600,000                      
Pfizer License and Share Purchase Agreements [Member] | SPR 206 [Member]                                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                                  
Receivable amount upon achievement of certain milestone                           $ 80,000,000                      
Issuance of stock, shares | shares                           2,362,348                      
Share price | $ / shares           $ 16.93               $ 16.93                      
Proceeds from sale of common stock to related party                           $ 40,000,000                      
Pfizer License and Share Purchase Agreements [Member] | Research And Development Services Related To Upcoming Milestones [Member]                                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                                  
Performance Obligation Allocated Transaction Price                 $ 4,100,000         11,100,000                      
Pfizer License and Share Purchase Agreements [Member] | License and Know-How Transfer [Member]                                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                                  
Performance Obligation Allocated Transaction Price                           $ 1,400,000